Research Topics
Species | P D DelmasSummaryCountry: France Publications
| Collaborators
|
Detail Information
Publications
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trialPierre D Delmas
University of Claude Bernard of Lyon, Hopital Edouard Herriot, Service de Rhumatologie et de Pathologie Osseuse, Lyon 69437, France
J Clin Endocrinol Metab 87:3609-17. 2002..The decreased vertebral fracture risk in yr 4 alone was not different from that observed in the first 3 yr...
Treatment of postmenopausal osteoporosisPierre D Delmas
Claude Bernard University of Lyon and INSERM Research Unit 403, France
Lancet 359:2018-26. 2002..Non-pharmacological interventions include adequate calcium intake and diet, selected exercise programmes, reduction of other risk factors for osteoporotic fractures, and reduction of the risk of falls in elderly individuals...
Different effects of antiresorptive therapies on vertebral and nonvertebral fractures in postmenopausal osteoporosisP D Delmas
INSERM Research Unit 403 and Claude Bernard University of Lyon, Lyon, France
Bone 30:14-7. 2002..These discrepancies stress the differences in the pathogenesis of vertebral and nonvertebral fractures as discussed below, and the need to further investigate the mechanisms of action of various antiresorptive agents...
Monitoring individual response to hormone replacement therapy with bone markersP D Delmas
INSERM Research Unit 403, Hopital E Herriot, Lyon, France
Bone 26:553-60. 2000..Our data suggest that bone turnover markers can be used to monitor the BMD response to HRT at the individual level. Whether such monitoring could improve long-term compliance to HRT should be tested prospectively...
The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosisP D Delmas
INSERM Research Unit 403 and Claude Bernard University of Lyon, France
Osteoporos Int 13:1-5. 2002..A relative margin of non-inferiority of 20-30% is suggested, to be discussed on a case by case basis...
Effects of a new selective estrogen receptor modulator (MDL 103,323) on cancellous and cortical bone in ovariectomized ewes: a biochemical, histomorphometric, and densitometric studyP Chavassieux
, , Lyon, France
J Bone Miner Res 16:89-96. 2001..These effects on cortical bone were reflected by changes in biochemical markers. MDL markedly reduces bone turnover and increases BMD suggesting that this new agent may prevent postmenopausal bone loss...
Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damageP Garnero
INSERM Research Unit 403, Lyon, France
Ann Rheum Dis 60:619-26. 2001..The clinical performance of these two new markers was compared with that of a panel of other established biochemical markers of connective tissue metabolism...
Cross-sectional evaluation of bone metabolism in menP Szulc
INSERM Research Unit 403, Lyon, France
J Bone Miner Res 16:1642-50. 2001..After the age of 60 years, bone resorption markers--but not bone formation markers--increase in some men and are associated with lower BMD, suggesting that this imbalance is responsible for increasing bone loss in elderly men...
Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective studyP Garnero
INSERM Unit 403, Hopital E Herriot, Lyon, France
Osteoporos Int 8:563-9. 1998..If DXA is not available, the combination of history of fracture and urinary CTX performs as well as hip BMD to assess hip fracture risk in elderly women...
The collagenolytic activity of cathepsin K is unique among mammalian proteinasesP Garnero
INSERM Unit 403, Hopital E Herriot, Pav F, 69437 Lyon Cedex 03, France
J Biol Chem 273:32347-52. 1998..This property of cathepsin K is unique among mammalian proteinases and is reminiscent of bacterial collagenases. It is likely to be responsible for the key role of cathepsin K in bone resorption...
Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnoverP D Delmas
INSERM Research Unit 403, Claude Bernard University of Lyon, Lyon, France
Bone 39:237-43. 2006..Teriparatide is a bone formation agent that increases bone turnover and mass, resulting in an increase in bone strength and a decrease in fracture risk...
Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown productsP Garnero
INSERM Unit 403, Department of Immunology, Hopital Edouard Herriot, Lyon, France
Bone 24:381-5. 1999..Bone formation appears to be reduced both in patients with and without joint destruction, whereas resorption is increased only in patients with joint destruction in relation to disease activity...
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE studyP D Delmas
Inserm Unite 403, Physiopathologie, Hopital Edouard Herriot, 5 Place d Arsonval, Lyon Cedex 3, France
Osteoporos Int 15:792-8. 2004..Thus, intermittent ibandronate has potential to become an important alternative to currently licensed bisphosphonates in postmenopausal osteoporosis...
Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal womenP Garnero
INSERM U 403, Hopital E Herriot, Lyon, France
J Clin Endocrinol Metab 84:2390-7. 1999..The delayed decrease in bone formation observed with intranasal E2 compared to oral E2 may be related to different effects on serum IGF-I levels...
Association between collagen cross-links and trabecular microarchitecture properties of human vertebral boneS Viguet-Carrin
INSERM Research Unit 831 and Claude Bernard University of Lyon, Lyon, France
Bone 46:342-7. 2010..Thus, vertebral fragility may not only be due to alterations in bone architecture but also to modification of collagen cross-link patterns thereby influencing bone's mechanical behavior...
Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal womenP D Delmas
INSERM Research Unit 831 and University of Lyon, Lyon, France
Osteoporos Int 19:1153-60. 2008..Tibolone increased lumbar spine and total hip BMD to a statistically significantly greater extent than raloxifene after two years of treatment...
Semiquantitative evaluation of prevalent vertebral deformities in men and their relationship with osteoporosis: the MINOS studyP Szulc
INSERM Research Unit 403, Lyon, France
Osteoporos Int 12:302-10. 2001..Grade 1 deformities are often either false positive or deformities related to nonosteoporotic disease of the spine...
Bone loss in elderly men: increased endosteal bone loss and stable periosteal apposition. The prospective MINOS studyP Szulc
INSERM Research Unit 403, Hopital Edouard Herriot, Pavillon F, Place d Arsonval, 69437, Lyon, France
Osteoporos Int 18:495-503. 2007..The aim of this study was to assess age-related apparent net and endosteal bone loss as well as their morphological basis and age-related changes during a prospective follow-up in a large cohort of elderly men...
The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of boneP Garnero
INSERM Unit 403, Hopital E Herriot, Pav F, 69003 Lyon, France
Bone 28:461-4. 2001..Measurement of type II collagen breakdown by a new urinary biochemical marker may be useful for in vivo assessment of the effects of drugs that potentially inhibit cartilage destruction...
Association of bone microarchitecture with parathyroid hormone concentration and calcium intake in men: the STRAMBO studyA Chaitou
INSERM Research Unit 1033, Hopital Edouard Herriot, Universite de Lyon 1, Place d Arsonval, 69437 Lyon, France
Eur J Endocrinol 165:151-9. 2011..We assessed the association of bone microarchitecture with calcium intake and serum concentrations of 25-hydroxycholecalciferol (25OHD) and parathyroid hormone (PTH) in men...
Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradationE Gineyts
INSERM Research Unit 403, , Lyon and. SYNARC, Lyon, France
Rheumatology (Oxford) 40:315-23. 2001..CONCLUSION: Glc-Gal-PYD may be useful for the clinical investigation of patients with joint disease...
Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosisP Garnero
INSERM Research Unit 403, Hopital E Herriot, Pavillon F, 69437 Lyon Cedex 03, France
Clin Chem 47:694-702. 2001..Our aim was to evaluate the technical and clinical performances of a new, fully automated assay for serum C-terminal cross-linking telopeptide of type I collagen (CTX), a marker of bone resorption...
Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY studyP Garnero
Synarc 16 rue Montbrillant 69003, Lyon, France
Bone 40:716-22. 2007..The aim of this study was to investigate the associations between serum 25-hydroxyvitamin D (25-OH D), bone turnover markers, bone mineral density (BMD), radius bone loss and incidence of fracture in postmenopausal women...
Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety resultsP D Delmas
University of Lyon and INSERM Research Unit 831, Lyon, France
Osteoporos Int 19:1039-45. 2008..Changes in bone mineral density and bone turnover markers were similar between treatments. Risedronate 75 mg twice monthly was effective and safe suggesting a new, convenient dosing schedule...
Thrombospondin binds to the surface of human osteosarcoma cells and mediates platelet-osteosarcoma cell interactionP Clezardin
INSERM U 234, , Lyon, France
Cancer Res 51:2621-7. 1991..6 x 10(6) cells/ml).(ABSTRACT TRUNCATED AT 400 WORDS)..
Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonatesC B Confavreux
INSERM Research Unit 831 and University of Lyon, Rheumatology Department, Hopital Edouard Herriot, Lyon, France
Bone 41:346-52. 2007..The bisphosphonate risedronate prevents anastrozole induced bone loss...
Racemization and isomerization of type I collagen C-telopeptides in human bone and soft tissues: assessment of tissue turnoverE Gineyts
INSERM U403, Hopital E Herriot, Pavillon F, Place d Arsonval, 69437 Lyon Cedex 03, France
Biochem J 345:481-5. 2000....
In osteoporotic women treated with strontium ranelate, strontium is located in bone formed during treatment with a maintained degree of mineralizationG Boivin
INSERM Unité 831, Faculté de Médecine R Laennec, Universite de Lyon, Lyon, France
Osteoporos Int 21:667-77. 2010..Strontium was shown to be dose-dependently deposited into this newly formed bone with preservation of the mineralization...
Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosisP Szulc
INSERM Research Unit 831, Hopital Edouard Herriot, Lyon, France
Osteoporos Int 19:1683-704. 2008..The aim was to analyse data on the use of biochemical bone turnover markers (BTM) in postmenopausal osteoporosis...
Structural determinants of hip fracture in elderly women: re-analysis of the data from the EPIDOS studyP Szulc
INSERM 403 Research Unit, Hopital Edouard Herriot, Pavillon F Place d Arsonval, 69437, Lyon, France
Osteoporos Int 17:231-6. 2006..Thus, the independent contribution of the external diameter of the femoral neck to the risk of hip fracture cannot be reliably estimated by this technique...
High bone turnover is associated with accelerated bone loss but not with increased fracture risk in men aged 50 and over: the prospective MINOS studyP Szulc
INSERM Research Unit 831, Hopital Edouard Herriot, Pavillon F, 69437 Lyon, France
Ann Rheum Dis 67:1249-55. 2008..The morphological basis of such a relationship is unknown. The objective of this study was to evaluate the association between baseline BTM levels and subsequent bone loss and fracture risk in men...
The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradationP Garnero
INSERM Unit 403, Hopital E Herriot, Lyon, France
J Bone Miner Res 18:859-67. 2003..We conclude that the generation of ICTP and CTX depends on different collagenolytic pathways. This finding may explain why these two markers may discriminate between different bone pathologies...
The role of collagen in bone strengthS Viguet-Carrin
INSERM Research Unit 403 and Claude Bernard University, Lyon, France
Osteoporos Int 17:319-36. 2006..To illustrate the role of the crosslinking process of collagen in bone strength, clinical disorders associated with bone collagen abnormalities and bone fragility, such as osteogenesis imperfecta and osteoporosis, are described...
Vitamin D receptor gene polymorphisms are associated with the risk of fractures in postmenopausal women, independently of bone mineral densityP Garnero
Institut National de la Santé et de la Recherche Médicale Research Unit 403, Hopital E Herriot, Pavillon F, 69437 Lyon Cedex 03, France
J Clin Endocrinol Metab 90:4829-35. 2005..Vitamin D receptor (VDR) gene polymorphisms explain only a small part of the genetic influence on the level of bone mineral density (BMD), whereas their effect on fracture remains uncertain...
A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnoverP Garnero
INSERM Unit 403, Hopital E Herriot, Lyon, France
Bone 24:603-9. 1999..Because this model is independent of the study design, it should be broadly applicable...
Cross-sectional and longitudinal assessment of pre- and postmenopausal bone loss with a portable forearm X-ray device: the Ofely studyF Duboeuf
INSERM Research Unit 403, Hopital E Herriot, Lyon, France
Bone 26:131-5. 2000....
Glutamate receptors are expressed by bone cells and are involved in bone resorptionC Chenu
INSERM, Unit 403, Hopital E Herriot, Lyon, France
Bone 22:295-9. 1998..These results suggest a possible new mechanism for regulating osteoclast activity and indicate that excitatory amino acids such as glutamate may be important local regulators of bone cell functions...
Risk factors for peripheral fractures vary by age in older men--the prospective MINOS studyS Blaizot
INSERM 831 Research Unit, Universite de Lyon, Lyon, France
Osteoporos Int 22:1755-64. 2011..Identification of older men at high risk of peripheral fracture can be improved by assessing prevalent fractures (men aged ≤ 65), history of falls (men aged >65), bone width, and aortic calcifications...
The role of mineralization and organic matrix in the microhardness of bone tissue from controls and osteoporotic patientsG Boivin
INSERM Unité 831, Universite de Lyon, Faculté de Médecine R Laennec, Lyon, France
Bone 43:532-8. 2008..Bone microhardness is linked to Young's modulus of bone and is strongly correlated to mineralization, but the organic matrix accounts for about one third of its variance...
Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebraeS Viguet-Carrin
, Lyon, France
Bone 39:1073-9. 2006..83, P = 0.015). These findings indicate that post-translational modifications of type I collagen have an impact on skeletal fragility...
Role of sex steroids in the regulation of bone morphology in men. The MINOS studyP Szulc
INSERM Research Unit 403, , place d'Arsonval, 69437, Lyon, France
Osteoporos Int 15:909-17. 2004....
Effectiveness of instant vertebral assessment to detect prevalent vertebral fractureR D Chapurlat
Department of Rheumatology and Bone Disease and INSERM Unit 403, Hopital E Herriot, 5 Place d Arsonval, 69437, Lyon, Cedex 03, France
Osteoporos Int 17:1189-95. 2006....
Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritisJ C Rousseau
INSERM Unit 403, Pavillon F, Hopital E Herriot, Lyon, France
Osteoarthritis Cartilage 12:440-7. 2004..In addition, we investigated circulating forms recognized by antiserum IIA in pools of serum from healthy adults, patients with OA and patients with RA...
Biochemical markers of bone formation reflect endosteal bone loss in elderly men--MINOS studyP Szulc
INSERM 403 Research Unit, , Claude Bernard University, Lyon, France
Bone 36:13-21. 2005..In contrast, they do not reflect the periosteal bone formation, probably because the periosteal surface is smaller and has a slower remodelling rate than the endosteal surface...
Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritisE Gineyts
INSERM Research Unit 403, Hopital Edouard Herriot, Pavillon F, Place d Arsonval, 69003 Lyon, France
Ann Rheum Dis 63:857-61. 2004....
An in vitro model to test the contribution of advanced glycation end products to bone biomechanical propertiesS Viguet-Carrin
INSERM Research Unit 831 University of Lyon, Lyon, France
Bone 42:139-49. 2008..AGE concentration did not influence bending mechanical properties; however, the simple 3-point bending test we used was likely inadequate to demonstrate effects of AGEs on mechanical properties...
FRAX® probabilities and risk of major osteoporotic fracture in FranceC M Couris
Pôle IMER, Hospices Civils de Lyon, Lyon, France
Osteoporos Int 23:2321-7. 2012....
Simple and sensitive method for quantification of fluorescent enzymatic mature and senescent crosslinks of collagen in bone hydrolysate using single-column high performance liquid chromatographyS Viguet-Carrin
INSERM Research Unit 831, Claude Bernard University of Lyon, Lyon, France
J Chromatogr B Analyt Technol Biomed Life Sci 877:1-7. 2009..2 pmol for the pyridimium crosslinks and 0.02 pmol for the pentosidine. The inter- and intra-assay coefficients of variation were as low as 5% and 2%, respectively, for all crosslinks...
Cortical and trabecular bone distribution in the femoral neck in osteoporosis and osteoarthritisH Blain
INSERM Unit 831 and Université de Lyon, Lyon, France
Bone 43:862-8. 2008..Furthermore, the spatial distribution of the trabeculae differs between OP and OA whereas cortical thinning is homogenous...
[New treatments in osteoporosis]R Chapurlat
Service de rhumatologie et de pathologie osseuse et Inserm U403, Pavillon F, Hopital Edouard Herriot, 5, place Arsonval, 69437 Lyon 03, France
Rev Med Interne 25:S573-9. 2004..In the next five years, new SERMs and inhibitors of RANK-ligand might be new treatment options...
Biochemical assessment of bone turnover and bone fragility in menP Szulc
INSERM Research Unit 831, University of Lyon, Lyon, France
Osteoporos Int 18:1451-61. 2007..Osteoporosis in men is less studied than in women. Few data concern biochemical bone turnover markers (BTM) in men and their potential use...
Bone width is correlated positively with the upper to the lower segment ratio in elderly men--the MINOS studyP Szulc
INSERM Research Unit 403, Hopital Edouard Herriot, Pavillon F, Place d Arsonval, 69437 Lyon, France
Bone 40:194-9. 2007..Given methodological limitations, these results need to be confirmed in a younger and more representative group of men...
Homocysteine and fracture risk in postmenopausal women: the OFELY studyM A Périer
INSERM Research Unit 831, Pavillon F, Hopital E Herriot, 69437 Lyon Cedex 03, France
Osteoporos Int 18:1329-36. 2007..After adjustment for age, there was no significant relation between the plasma level of homocysteine and the subsequent risk of fracture...
Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by diseaseP Chavassieux
Institut National de la Santé et de la Recherche Médicale Unit 831, Pavillon F, Hopital E Herriot, 69437 Lyon Cedex 08, France
Endocr Rev 28:151-64. 2007..Observations in patients and in animal models provide insights on the biomechanical consequences of these illnesses and the nature of the qualities of bone that determine its strength...
An immunoassay for type I collagen alpha 1 helicoidal peptide 620-633, a new marker of bone resorption in osteoporosisP Garnero
INSERM Research Unit 403, Hôpital E Herriot Pavillon F, 69437 Lyon Cedex 03, France
Bone 32:20-6. 2003..The test was a sensitive indicator of the antiresorptive effects of bisphosphonate and estrogens in postmenopausal women. This new bone resorption marker should be useful for the clinical investigation of patients with osteoporosis...
Biochemical markers of bone turnover in menP Szulc
INSERM Research Unit 403, Claude Bernard University, Lyon, France
Calcif Tissue Int 69:229-34. 2001..Thus, antiresorptive therapy may be of interest in the prevention and treatment of osteoporosis in men. Further studies are necessary to determine if bone resorption markers predict the risk of fragility fractures in elderly men...
Glucocorticoid-induced inhibition of osteoblastic bone formation in ewes: a biochemical and histomorphometric studyP Chavassieux
, , Lyon, France
Osteoporos Int 3:97-102. 1993..The bone formation rate (BFR/B.Pm) also decreased by 84% and the adjusted apposition rate (Aj.AR) by 80%. The increase in the total formation period was mainly due to an increase in the inactive period.(ABSTRACT TRUNCATED AT 250 WORDS)..
Is the predictive power of previous fractures for new spine and non-spine fractures associated with biochemical evidence of altered bone remodelling? The EPOS study. European Prospective Osteoporosis StudyP Vergnaud
U INSERM 403, Lyon, France
Clin Chim Acta 322:121-32. 2002..6 - 12-fold even after adjusting for BMD. We examined the possibility that biochemical marker levels were associated with this unexplained BMD-independent element of fracture risk...
Expression of Semaphorin-3A and its receptors in endochondral ossification: potential role in skeletal development and innervationC Gomez
INSERM, Unit 403, Lyon, France
Dev Dyn 234:393-403. 2005..Expression patterns suggest Plexin-A3/Neuropilin-1 as a candidate receptor in target cells for the regulation of bone innervation by Semaphorin-3A...
Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritisH Marotte
Hospices Civils de Lyon bioMérieux Research Unit on Rheumatoid Arthritis, Hospital Edouard Herriot, Lyon, France
Ann Rheum Dis 68:1197-200. 2009....
Urinary type II collagen C-telopeptide levels are increased in patients with rapidly destructive hip osteoarthritisP Garnero
INSERM Research Unit 403, Lyon, France
Ann Rheum Dis 62:939-43. 2003..To compare type II collagen degradation using a new urinary specific marker in patients with rapidly destructive and those with slowly progressive hip OA...
Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal womenP Garnero
INSERM Research Unit 403 and Synarc, Lyon, France
J Musculoskelet Neuronal Interact 4:50-63. 2004..Further studies in osteoporosis should explore the changes in these biochemical parameters of bone matrix as they may represent a key component of bone quality...
Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trialP D Delmas
University Claude Bernard of Lyon, and INSERM Research Unit 403, Hopital Edouard Herriot, Lyon, France
Bone 33:522-32. 2003..These fractures may reflect architectural deterioration, independent of BMD, leading to increased skeletal fragility...
Beyond hip: importance of other nonspinal fracturesP D Delmas
INSERM Research Unit 403 and Université Claude Bernard Lyon 1, Lyon, France
Am J Med 120:381-7. 2007..It is the clinician's responsibility to attend to and recognize that nonspinal, nonhip fractures are usually associated with osteoporosis and should be treated...
Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analysesP D Delmas
INSERM Research Unit 403, Claude Bernard University of Lyon, Lyon, France
J Bone Miner Res 19:330-7. 2004..Many factors may affect the outcome of such analyses. Our work explores some of these factors and illustrates the need for caution in interpreting the results of meta-analyses...
Decorin inhibits cell migration through a process requiring its glycosaminoglycan side chainB Merle
INSERM Research Unit 403, Pavillon F, Hopital Edouard Herriot, 69437 Lyon Cedex 03, France
J Cell Biochem 75:538-46. 1999..dermatan-sulfate chains), and is independent of a steric hindrance effect exerted by its glycosaminoglycan side chains...
Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trialP J Meunier
Hopital Edouard Herriot, 69437 Lyon, France
J Clin Endocrinol Metab 87:2060-6. 2002..All tested doses were well tolerated; the 2 g/d dose was considered to offer the best combination of efficacy and safety. In conclusion, SR therapy increased vertebral BMD and reduced the incidence of vertebral fractures...
Bone microdamage: a clinical perspectiveR D Chapurlat
INSERM Research Unit 831, Universite de Lyon, Hopital E Herriot, Hospices Civils de Lyon, 69437 Lyon Cedex 03, France
Osteoporos Int 20:1299-308. 2009..Microdamage accumulation due to fatigue loading may lead to fracture. In addition, several studies using animal models have suggested in recent years that bisphosphonates might increase microdamage accumulation...
Complex formation of human thrombospondin with osteonectinP Clezardin
Institut National de la Sante et de la Recherche Medicale, Faculte de Medecine Alexis Carrel, Lyon, France
Eur J Biochem 175:275-84. 1988....
Protein-S, a vitamin K-dependent protein, is a bone matrix component synthesized and secreted by osteoblastsC Maillard
INSERM U 234, Hopital Edouard Herriot, Lyon, France
Endocrinology 130:1599-604. 1992..This finding raises the intriguing possibility that protein-S might play a role in bone turnover and bone mass...
Association between a functional interleukin-6 gene polymorphism and peak bone mineral density and postmenopausal bone loss in women: the OFELY studyP Garnero
INSERM Research Unit 403, Hopital E Herriot, Lyon, France
Bone 31:43-50. 2002..Larger long-term studies are necessary to assess adequately the relationships between IL-6 genotype, rate of bone loss, and risk of fracture...
Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelateMonique E Arlot
INSERM, Universite Lyon 1, Lyon, France
J Bone Miner Res 23:215-22. 2008..Hence, these effects may explain the decreased fracture rate...
Recognizing and reporting osteoporotic vertebral fracturesMikayel Grigoryan
Osteoporosis and Arthritis Research Group, Department of Radiology, University of California San Francisco, 350 Parnassus Avenue, 94117, San Francisco, CA, USA
Eur Spine J 12:S104-12. 2003....
NICE recommendations for the prevention of osteoporotic fractures in postmenopausal womenPierre D Delmas
INSERM Research Unit 831 and University of Lyon, Hopital E. Herriot, Pavillon F, 69437 Lyon Cedex 03, France
Bone 42:16-8. 2008
Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosisAlan L Burshell
Ochsner Clinic Foundation, New Orleans, LA 70121, USA
Curr Med Res Opin 24:807-13. 2008..To evaluate the relationship between bone mass and risk of breast cancer and to determine the effect of raloxifene therapy on breast cancer incidence in women categorized by bone mass into low bone mass and osteoporosis subgroups...
Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: the OFELY studyElisabeth Sornay-Rendu
INSERM Research Unit 403, Pavillon F, E. Herriot Hospital, 69437 Lyon Cedex 03, France
Bone 33:159-66. 2003....
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosisPierre D Delmas
INSERM Research Unit 831 and University of Lyon, Lyon, France
Bone 42:36-42. 2008..This randomized, double-blind, multi-center study was designed to assess the efficacy and safety of a single 150 mg risedronate once-a-month oral dose compared with the 5 mg daily regimen...
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structureRobert R Recker
School of Medicine, Creighton University, Omaha, Nebraska 68131, USA
J Bone Miner Res 23:6-16. 2008..Zoledronic acid reduced bone turnover by 63% and preserved bone structure and volume, with evidence of ongoing bone remodeling in 99% of biopsies obtained...
Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy studyRoland D Chapurlat
INSERM Research Unit 831 and Université de Lyon, Lyon, France
J Bone Miner Res 22:1502-9. 2007..We sought whether microdamage could rise in postmenopausal osteoporotic women on long-term bisphosphonates, as suggested by recent animal studies. We found few microcracks in iliac bone biopsies, despite a marked reduction in bone turnover...
NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesisBlandine Merle
INSERM Unit 403, Hopital E Herriot, Pavillon F, 69437 Lyon Cedex 03, France
J Cell Biochem 90:424-36. 2003..Altogether, our results indicate that osteoclast precursors express NMDAR that are involved in the osteoclast differentiation process through activation of the NF-kappa B pathway...
Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY studyPatrick Garnero
INSERM Research Unit 403, Hopital E Herriot, Lyon, France
J Bone Miner Res 18:1789-94. 2003..Seventy percent to 80% of women classified as having high bone turnover at baseline were similarly classified by the same methods 4 years later...
Biological markers in osteoarthritisJean Charles Rousseau
INSERM Research Unit on the Pathophysiology of Osteoporosis, Lyon, France
Nat Clin Pract Rheumatol 3:346-56. 2007..In this Review, we will use the recently proposed BIPED (i.e. burden of disease, investigative, prognostic, efficacy of intervention and diagnostic) classification of OA markers to describe the potential usage of a given marker...
Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled studyPaul D Miller
Colorado Center for Bone Research, Lakewood, Colorado 80227, USA
J Bone Miner Res 23:525-35. 2008..Osteoporosis is an increasingly common health concern in postmenopausal women. In a 2-yr phase III study, bazedoxifene prevented bone loss, reduced bone turnover, and was well tolerated in early postmenopausal women with normal or low BMD...
[Advances in the field of osteoporosis]Emmanuelle Vignot
Service de Rhumatologie et de Pathologie Osseuse, , ,
Rev Prat 57:1629-31. 2007
Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myelomaHans D Menssen
Department of Hematology and Oncology, Benjamin Franklin Klinik der Freien Universität, and St Hedwigs Krankenhaus, Berlin, Germany
J Clin Oncol 20:2353-9. 2002..This is the first double-blind, randomized, placebo-controlled study to assess the efficacy of ibandronate, a third-generation amino-bisphosphonate, in preventing SREs in advanced-stage multiple myeloma patients...
Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective studyPatrick Garnero
INSERM Unit 403, Hĵpital E. Herriot, Lyon, France
J Bone Miner Res 17:826-33. 2002..This suggests that alterations of type I collagen isomerization/racemization that can be detected by changes in urinary CTX ratios may be associated with increased skeletal fragility...
[Osteoporosis in the aged male]Pawel Szulc
, , Pavillon F, place d'Arsonval, 69437 Lyon
Presse Med 31:1760-9. 2002..In a randomised study, alendronate increased BMD and reduced the incidence of vertebral fractures. Alendronate and risedronate were also effective in the prevention and treatment of cortisone-induced osteoporosis in men...
The effects of tibolone in older postmenopausal womenSteven R Cummings
San Francisco Coordinating Center and the California Pacific Medical Center Research Institute, San Francisco, USA
N Engl J Med 359:697-708. 2008..Tibolone has estrogenic, progestogenic, and androgenic effects. Although tibolone prevents bone loss, its effects on fractures, breast cancer, and cardiovascular disease are uncertain...
Review of ibandronate in the treatment of osteoporosisRoland D Chapurlat
Department of Rheumatology and Bone Diseases, Hôpital E Herriot and Claude Bernard University of Lyon, 5 Place d Arsonval, France
Expert Opin Pharmacother 4:391-6. 2003..v. every 3 months. Thus, ibandronate can be considered as a promising new option for the treatment of postmenopausal osteoporotic women...
Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trialJean Yves Reginster
University of Liege, Liege, Belgium
Arthritis Rheum 58:1687-95. 2008..This study was undertaken to assess the effect of strontium ranelate on nonvertebral and vertebral fractures in postmenopausal women with osteoporosis in a 5-year, double-blind, placebo-controlled trial...
Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseasesPierre D Delmas
Université de Lyon and INSERM Research Unit 831, Lyon, France
J Clin Densitom 11:325-38. 2008..The results of these human trials will also be discussed...
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA studyJohn A Eisman
Garvan Institute of Medical Research, St Vincent s Campus and University of New South Wales, Sydney, Australia
J Rheumatol 35:488-97. 2008..We report the effects on lumbar spine and proximal femur bone mineral density (BMD) and bone resorption markers over 2 years...
Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational studyRonald Emkey
Radiant Research, Wyomissing, Pennsylvania 19610, USA
Arthritis Rheum 48:1102-8. 2003..To evaluate the effects of discontinuing or continuing alendronate (ALN) therapy on bone mineral density (BMD) after patients on a long-term regimen of glucocorticoids (GCs) completed a 1-year treatment period with ALN...
Low skeletal muscle mass is associated with poor structural parameters of bone and impaired balance in elderly men--the MINOS studyPawel Szulc
INSERM Unit 403, Lyon, France
J Bone Miner Res 20:721-9. 2005....
Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosisAurelie Fontana
, place d'Arsonval, Pavilion F, 69437 Lyon, Cedex 03, France
Endocrinol Metab Clin North Am 32:219-32. 2003....
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosisDennis M Black
University of California, San Francisco, San Francisco, CA 94107, USA
N Engl J Med 356:1809-22. 2007..We assessed the effects of annual infusions of zoledronic acid on fracture risk during a 3-year period...
Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture riskSomnath Sarkar
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, USA
J Bone Miner Res 19:394-401. 2004..After adjustment of each significant baseline variable, the percent change in OC was better able to predict the reduction in vertebral fracture risk than the percent change in femoral neck BMD in patients treated with raloxifene...
Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapyPierre D Delmas
Claude Bernard University of Lyon and INSERM Research Unit 403, Lyon, France
Bone 34:599-604. 2004..Further studies are needed to define the structural basis of the fracture risk reduction...
Association between spine disc degeneration and type II collagen degradation in postmenopausal women: the OFELY studyPatrick Garnero
INSERM Research Unit 403, Synarc, Lyon, France
Arthritis Rheum 50:3137-44. 2004....
Rate of forearm bone loss is associated with an increased risk of fracture independently of bone mass in postmenopausal women: the OFELY studyElisabeth Sornay-Rendu
INSERM Research Unit 403 and Claude Bernard University, Lyon, France
J Bone Miner Res 20:1929-35. 2005..In 671 postmenopausal women from the OFELY cohort, we found that the rate of bone loss was significantly associated with fracture risk independently of other well-known predictors including BMD and previous fractures...
Anti-vertebral fracture efficacy of raloxifene: a meta-analysisEgo Seeman
Department of Endocrinology, University of Melbourne, Austin Hospital, Heidelberg, 3084, Melbourne, Victoria, Australia
Osteoporos Int 17:313-6. 2006..Odds ratio estimates (95% CI) were 0.60 (0.49, 0.74) for RLX60 and 0.51 (0.41, 0.64) for RLX120/150. From these data we infer that raloxifene consistently reduces the risk of vertebral fracture in postmenopausal women...
